Sayyed Hamed Shahoei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sayyed Hamed Shahoei has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Erik Russell Nelson
Department of Molecular and Integrative Physiology, University of Illinois Urbana Champaign, Illinois, USA
3 shared publications - Hashni Epa Vidana Gamage
Department of Molecular and Integrative Physiology, University of Illinois Urbana Champaign, Illinois, USA
3 shared publications - Adam T. Nelczyk
Department of Molecular and Integrative Physiology, University of Illinois Urbana Champaign, Illinois, USA
2 shared publications - Amanda J. Smith
Department of Chemistry, University of Illinois at Urbana-Champaign, Illinois, USA
2 shared publications - Anasuya Das Gupta
Department of Molecular and Integrative Physiology, University of Illinois Urbana Champaign, Illinois, USA
2 shared publications - Claire P. Schane
Department of Molecular and Integrative Physiology, University of Illinois Urbana Champaign, Illinois, USA
2 shared publications
Latest Publications
- Open Access
- 26 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (39) , eads3731
Nanomedicine targeting PPAR in adipose tissue macrophages improves lipid metabolism and obesity-induced metabolic dysfunction
Excess body fat leads to an overabundance of adipose tissue macrophages (AT MΦs) with altered phenotypes that play pathogenic roles in obesity comorbidities including diabetes and cancer. Peroxisome proliferator–activated receptors (PPARs) are leading targets to modulate AT MΦ phenotype. Here, we developed a dextran-based nanomedicine that delivers PPARα/γ agonists to AT MΦs and improves obesity and diabetic phenotypes in vivo. Within 1 week of treatment, AT MΦs decreased and became lipid laden, while extracellular vesicles secreted from AT decreased and reduced in lipid content. Within 2 weeks, glucose tolerance returned to levels of lean controls, followed by weight loss and reduced food intake. After 4 weeks, AT browning and amelioration of hepatic steatosis were evident. The physiological shifts were reproducible in three rodent models of obesity, spanning sexes and gonadal status. Effects were enhanced for the targeted nanomedicine compared with free drugs at equivalent doses, supporting the hypothesis that targeted PPAR activation in AT MΦs benefits systemic metabolism.
- 26 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (39) , eads3731
Open AccessNanomedicine targeting PPAR in adipose tissue macrophages improves lipid metabolism and obesity-induced metabolic dysfunction
Excess body fat leads to an overabundance of adipose tissue macrophages (AT MΦs) with altered phenotypes that play pathogenic roles in obesity comorbidities including diabetes and cancer. Peroxisome proliferator–activated receptors (PPARs) are leading targets to modulate AT MΦ phenotype. Here, we developed a dextran-based nanomedicine that delivers PPARα/γ agonists to AT MΦs and improves obesity and diabetic phenotypes in vivo. Within 1 week of treatment, AT MΦs decreased and became lipid laden, while extracellular vesicles secreted from AT decreased and reduced in lipid content. Within 2 weeks, glucose tolerance returned to levels of lean controls, followed by weight loss and reduced food intake. After 4 weeks, AT browning and amelioration of hepatic steatosis were evident. The physiological shifts were reproducible in three rodent models of obesity, spanning sexes and gonadal status. Effects were enhanced for the targeted nanomedicine compared with free drugs at equivalent doses, supporting the hypothesis that targeted PPAR activation in AT MΦs benefits systemic metabolism.
- Open Access
- 27 June 2024
- Published by Elsevier in Cancer Letters
- Vol. 597, 217086
Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells
- 27 June 2024
- Published by Elsevier in Cancer Letters
- Vol. 597, 217086
Open AccessDevelopment of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells
- Open Access
- 20 June 2024
- Published by Elsevier in Cancer Letters
- Vol. 597, 217042
NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors
- 20 June 2024
- Published by Elsevier in Cancer Letters
- Vol. 597, 217042
Open AccessNR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors